EFFECTIVENESS AND SAFETY OF INACTIVATED COVID-19 VACCINE IN PATIENTS WITH ULCERATIVE COLITIS RECEIVING ANTI-TNF COMPARED TO HEALTHY EGYPTIAN POPULATION | ||||
| Journal of the Egyptian Society of Parasitology | ||||
| Article 5, Volume 54, Issue 1, April 2024, Page 25-30 PDF (2.54 MB) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/jesp.2024.351288 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
| MOSTAFA ABDALFATTAH SHAMKH1; AMR ALAA EL-DIN1; NADIA ABDELAATY ABDELKADER1; HEBA ISMAIL SAAD1; MENNA ALLAH ZAKARIA ABOU ELWAFA2 | ||||
| 1Department of Tropical Medicine, Faculty of Medicine, Ain Shams University Hospitals, Cairo 11566, Egypt | ||||
| 2Department of Clinical Pathology, Faculty of Medicine, Ain Shams University Hospitals, Cairo 11566, Egypt | ||||
| Abstract | ||||
| Ulcerative colitis (UC) has been proven to have an economic and physical burden upon patients, with an associated mortality of up to 2.9%. However, morbidity and mortality have peaked since the breakout Coronavirus disease 2019 )COVID-19( pandemic as result of direct relationship between Inflammatory bowel disease (IBD) severity and adverse outcome from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. This study evaluated the efficacy and safety of inactivated COVID 19 vaccine (e.g. Sinopharm) in UC patients receiving anti-tumor necrosis factor (TNF) as compared to normal hea lthy population receiving the same type of vaccine 3 months after the last dose of vaccination. The results showed those twenty patients with ulcerative colitis and on Anti TNF treatment (GA), and 20 healthy controls (GB). In GA; the mean age was (31.65) years, included 12 females (60%) and 8 males (40%). While in GB; the mean age was (30.55) years, with 11 males (55%) and 9 females (45%) without significant difference between both as to age (P=0.459) or sex (P=0.619). In GA only 16 (80%) had positive anti-spike IgG versus 18 posit- ives in GB (90%) without significant difference. Anti-spike IgG titre after 3 months with median ranges of 33.5 (RU/ml) in IBD patients and 44.5 (RU/ml) in controls with significant difference between both (P=0.025). There was no significant difference between both groups as to pain at injection site, skin allergy and generalized symptoms (fatigue, fever, chills, headache, muscles and joints pain). | ||||
| Keywords | ||||
| Egypt; Patients; Ulcerative colitis; COVID-19; Vaccine; Anti-spike IgG | ||||
|
Statistics Article View: 25 PDF Download: 23 |
||||
